



**PROGRAM**  
of the 12th Pan-Eurasian Conference Organized by the Eurasian Association of Therapists

April 22, 2021 Almaty (online)  
**Comorbid Patient and the Pandemic**

<p>11:00-11:20 <i>(Almaty)</i> 8:00-08:20 <i>(MSK)</i></p>	<p><b>Opening session</b> <b>Hall 1 (Almaty)</b> Welcome speech: A. Arutyunov, Secretary General of the Eurasian Association of Therapists (Moscow, Russia) T. Nurgozhin, Rector of Asfendiyarov Kazakh National Medical University (Almaty, Kazakhstan)</p>
<p>11:20-12:50 <i>(Almaty)</i> 8:20-09:50 <i>(MSK)</i></p>	<p><b>Plenary session</b> <b>Hall 1 (Almaty)</b> <b>Optimal strategies for protecting patients with atrial fibrillation</b> <i>(with Bayer's support)</i> G. Arutyunov (Moscow, Russia) <b>Generalized data of the first Eurasian COVID-19 registry</b> E. Tarlovskaya (Nizhny Novgorod, Russia) <b>Anticoagulants, hormones, and target treatment of internal organs: not all swans are white</b> A. Arutyunov (Moscow, Russia) <b>Thromboembolia of the pulmonary artery and deep vein thrombosis</b> A. Sugraliev (Almaty, Kazakhstan)</p>
<p>12:55-13:15 <i>(Almaty)</i> 9:55-10:15 <i>(MSK)</i></p>	<p><b>Panel discussion. Pro vs Contra</b> <b>Hall 1 (Almaty)</b> <i>(program to be specified)</i></p>
<p>13:15-13:30 <i>(Almaty)</i> 10:15-10:30 <i>(MSK)</i></p>	<p><b>Break</b></p>
<p>13:30-14:45 <i>(Almaty)</i> 10:30-11:45 <i>(MSK)</i></p>	<p><b>EAT workshops</b></p>

Hall 1 (Almaty)	Hall 2 (Tashkent)	Hall 3 (Minsk)	Hall 4 (Yerevan)	Hall 5 (Kishinev)
<p><b>Complex COVID-19 Issues</b></p> <p><b>Chair:</b> A. Arutyunov (Moscow, Russia)</p> <p><b>Pulmonary artery thrombosis or embolism in COVID-19?</b> Marco Cattaneo (Milan, Italy)</p> <p><b>Acute coronary failure in COVID-19 patients (15-minute presentation)</b> O. Kolodyazhnaya (Moscow, Russia)</p> <p><b>Anticoagulant agents: dosing issues</b> A. Arutyunov (Moscow, Russia)</p> <p><b>Interstitial fibrosis: persisting lung inflammation</b> M. Boldina (Nizhny Novgorod, Russia)</p>	<p><b>Unstable patients: internal medicine clinical cases</b></p> <p><b>Chairpersons:</b> Sh. Zhangelova (Almaty, Kazakhstan), A. Kaskabayeva (Semey, Kazakhstan)</p> <p><b>High-risk thromboembolia of the pulmonary artery. Diagnostics and treatment</b> Zh. Urazalina (Semey, Kazakhstan)</p> <p><b>Unsolved issues of chronic heart failure management</b> B. Zholdin (Aktobe, Kazakhstan)</p> <p><b>Problems with diagnosing thromboembolia of the pulmonary artery when a patient suffers from chronic heart failure</b> A. Sugraliev (Almaty, Kazakhstan)</p> <p><b>Chronic heart failure and diabetes mellitus: new facts</b> <i>(under SANTO's support)</i> A. Rakisheva (Almaty, Kazakhstan)</p>	<p><b>Modern capabilities of anticoagulant treatment for patients with atrial fibrillation</b> <i>(under Bayer's support)</i></p> <p><b>Chair:</b> G. Arutyunov (Moscow, Russia)</p> <p><b>From the strategy to tactics, from the medicine to a patient. Treatment of aged patients with AF</b> G. Arutyunov (Moscow, Russia)</p> <p><b>Only heart attack? What else an aged patient with AF should be protected from</b> Ya. Orlova (Moscow, Russia)</p> <p><b>A nephrologist's view of kidney failure in patients with AF. How to save and protect?</b> M. Batyushin (Rostov-on-Don, Russia)</p>	<p><b>Comorbid Cardiology. Workshop of the Republic of Belarus</b></p> <p><b>Chair: N. Mitkovskaya (Minsk, Belarus)</b></p> <p><b>Acute myocardial injury or ACS: differential diagnostics issues arising during the COVID-19 pandemic</b> N. Mitkovskaya (Minsk, Belarus)</p> <p><b>Cardiovascular risks a comorbid patient with syncope faces</b> E. Grigorenko (Minsk, Belarus)</p> <p><b>Comorbid patient with pericardial effusion</b> G. Arutyunov (Moscow, Russia)</p> <p><b>Modern possibilities of curing chronic heart failure</b> E. Kurlyandskaya (Minsk, Belarus) O. Polonetskiy (Minsk, Belarus)</p>	<p><b>Errors that could have been avoided, or How to improve hypertension pharmacotherapy</b></p> <p><b>Chair: V. Skibitskiy (Krasnodar, Russia)</b></p> <p><b>A doctor treating a patient with hypertension: errors, doubts, and misconceptions</b> V. Skibitskiy (Krasnodar, Russia)</p> <p><b>Resistant hypertension: errors that can be avoided</b> A. Fendrikova (Krasnodar, Russia)</p> <p><b>Hypertension and depression: what errors we commit</b> A. Skibitskiy (Krasnodar, Russia)</p>

14:45-15:30 (Almaty) 11:45-12:30 (MSK)	<b>Break</b>				
15:30-16:45 (Almaty) 12:30-13:45 (MSK)	<b>EAT workshops</b>				
	<b>Hall 1 (Almaty)</b>	<b>Hall 2 (Tashkent)</b>	<b>Hall 3 (Minsk)</b>	<b>Hall 4 (Yerevan)</b>	<b>Hall 5 (Kishinev)</b>
	<p><b>Research workshop. Where risk factors meet: mechanisms for tackling the threat</b> <i>(under Acino's support)</i></p> <p><b>Chair: A. Arutyunov (Moscow, Russia)</b></p> <p><b>Pre-diabetes and sympathetic overdrive; challenges and threats of the modern world</b> G. Arutyunov (Moscow, Russia)</p> <p><b>CVD triple risk management. What a doctor must know and be able to do?</b> A. Arutyunov (Moscow, Russia)</p>	<p><b>COVID-19 target organs damage</b></p> <p><b>Chair: I. Bakulin (Saint-Petersburg, Russia)</b></p> <p><b>Digestive organs damage in patients with COVID-19</b> I. Bakulin (Saint-Petersburg, Russia)</p> <p><b>Lungs damage in patients with COVID-19</b> M. Boldina (Nizhny Novgorod, Russia)</p> <p><b>CNS damage in patients with COVID-19</b> S. Khachatryan (Yerevan, Armenia)</p> <p><b>Myocardial damage in patients with COVID-19</b> E. Tarlovskaya (Nizhny Novgorod, Russia)</p> <p><b>Kidney damage in patients with COVID-19</b> M. Batyushin (Rostov-on-Don, Russia)</p>	<p><b>Contemporary Aspects of Practical Endocrinology</b></p> <p><b>Chairpersons: V. Salukhov (Saint-Petersburg, Russia), S. Shustov (Saint-Petersburg, Russia)</b></p> <p><b>Male aging-associated chronic androgen deficiency and myocardial revascularization</b> S. Shustov (Saint-Petersburg, Russia)</p> <p><b>Vicious circle of thyroidal metabolism in patients with CVD</b> A. Volkova (Saint-Petersburg, Russia), I. Abramova (Saint-Petersburg, Russia), G. Allamova (Saint-Petersburg, Russia)</p> <p><b>Sugar-reducing cardioprotectors: prospects for managing outcomes in patients with type 2 diabetes mellitus</b> V. Salukhov (Saint-Petersburg, Russia)</p>	<p><b>Workshop of the Armenian Association of Internal Medicine</b></p> <p><b>Chair: L. Manukyan (Yerevan, Armenia)</b></p> <p><b>COVID-19 and liver</b> A. Kazinyan (Yerevan, Armenia)</p> <p><b>Efficacy of famotidine in healing COVID-19</b> L. Manukyan (Yerevan, Armenia)</p> <p><b>Metabolic syndrome and COVID-19</b> E. Agazhanova (Yerevan, Armenia)</p> <p><b>Post-COVID sexual, psychological and emotional disorders</b> V. Shakhramanyan (Yerevan, Armenia)</p>	<p><b>Specific COVID-19 issues</b></p> <p><b>Chairpersons: B. Kosherova (Karaganda, Kazakhstan), A. Sugraliev (Almaty, Kazakhstan)</b></p> <p><b>COVID-19 survivor and vascular damages</b> Tatsuo Shimosawa (Tokyo, Japan)</p> <p><b>Tuberculosis amid the COVID-19 pandemic</b> A. Rakisheva (Almaty, Kazakhstan)</p> <p><b>COVID-19 peculiarities from the infectious disease specialist's point of view</b> A. Duseynova (Almaty, Kazakhstan)</p>

16:45-17:00 (Almaty) 13:45-14:00MSK	<b>Break</b>
17:00-19:00 (Almaty) 14:00-16:00 (MSK)	<b>Data blitz session</b> (under Bayer's support) <b>Hall 1 (Almaty)</b>
17:00-17:50 (Almaty) 14:00-14:50 (MSK)	<p><b>Systematic treatment for coronary heart disease. Data blitz session</b> (under Bayer's support)</p> <p><b>Prevention of cardiovascular accidents in patients with CHD</b> A. Arutyunov (Moscow, Russia)</p> <p><b>Five steps to diagnosing CHD in today's world</b> G. Arutyunov (Moscow, Russia)</p> <p><b>Possibility to intensify anti-thrombotic therapy in patients with CHD based on the recommendations and evidence base</b> Ya. Orlova (Moscow, Russia)</p> <p><b>How to give combined anti-thrombotic therapy to patients with CHD</b> O. Barbarash (Kemerovo, Russia)</p> <p><b>Which patients with CHD should be given combined anti-thrombotic therapy? Patient with pre-existing coronary heart disease and myocardial infarction</b> A. Lebedeva (Moscow, Russia)</p> <p><b>Which patients with CHD should be given combined anti-thrombotic therapy? Patient with coronary heart disease and myocardial infarction</b> N. Khasanov (Kazan, Russia)</p> <p><b>Which patients with CHD should be given combined anti-thrombotic therapy? Patient with coronary heart disease and polyvascular disease</b> E. Tarlovskaya (Nizhny Novgorod, Russia)</p> <p><b>How to efficiently help a patient with CHD? Assessment of anti-thrombotic therapy risks and their minimization</b> A. Komarov (Moscow, Russia)</p> <p><b>Patient with CHD after revascularization. Drug titration</b> I. Yavelov (Moscow, Russia)</p>
17:50-18:30 (Almaty) 14:50-15:30 (MSK)	<p><b>Expert discussions</b></p> <p>A. Arutyunov (Moscow, Russia), G. Arutyunov (Moscow, Russia), Ya. Orlova (Moscow, Russia), O. Barbarash (Kemerovo, Russia), A. Lebedeva (Moscow, Russia), N. Khasanov (Kazan, Russia), E. Tarlovskaya (Nizhny Novgorod, Russia), A. Komarov (Moscow, Russia), I. Yavelov (Moscow, Russia)</p>
18:30-19:00 (Almaty) 15:30-16:00 (MSK)	<b>Blitz data session (individual Zoom rooms)</b>
19:00-19:15 (Almaty) 16:00-16:15 (MSK)	<b>Break</b>
19:15-20:30 (Almaty) 16:15-17:30MSK	<b>EAT workshops</b>

	Hall 1 (Almaty)	Hall 2 (Tashkent)	Hall 3 (Minsk)	Hall 4 (Yerevan)	Hall 5 (Kishinev)
	<p><b>COVID-19 treatment</b></p> <p><b>Chair:</b> A. Arutyunov (Moscow, Russia)</p> <p><b>Target therapy</b> S. Zyryanov (Moscow, Russia)</p> <p><b>COVID plasma treatment</b> A. Boyarkov (Moscow, Russia)</p> <p><b>Antibodies as immune response in different age groups</b> V. Shustov (Moscow, Russia)</p>	<p><b>Results of new clinical research</b> <i>(program to be specified)</i></p> <p><b>Chair:</b> G. Manushakyan (Moscow, Russia)</p>	<p><b>Challenges posed by hypertension</b> <i>(under Servier's support)</i></p> <p><b>Chair:</b> G. Zhunusbekova (Almaty, Kazakhstan)</p> <p><b>Initiatives for Hypertension and COVID Prevention Dedicated to the World Hypertension Day</b> G. Zhunusbekova (Almaty, Kazakhstan)</p> <p><b>Efficacy of healing CVD. Challenges of 2021 the COVID-19 pandemic presents</b> E. Privalova (Moscow, Russia)</p>	<p><b>Special COVID-19 populations</b></p> <p><b>Chairpersons:</b> G. Shopaeva (Almaty, Kazakhstan), A. Sugraliev (Almaty, Kazakhstan)</p> <p><b>Pregnant women with COVID-19: Kazakh experience</b> G. Abuova (Shymkent, Kazakhstan)</p> <p><b>COVID impact on CV diseases</b> Plinio Cirillo (Naples, Italy)</p> <p><b>Comparative clinicopathologic characteristic of lung damage: COVID-19 and other bacterial and viral pneumonias</b> A. Goncharova (Almaty, Kazakhstan)</p>	<p><b>Multi-morbid patient: approaches of medical specialists from different fields. Workshop of the Republic of Moldova</b></p> <p><b>Chair:</b> A. Babin (Kishinev, Moldova)</p> <p><b>Stomach microflora and acid-related disorders</b> A. Babin (Kishinev, Moldova)</p> <p><b>Functional and genetic aspects of endothelial dysfunction to be considered to effectively cure patients with COPD of pulmonary hypertension</b> K. Martynyuk (Kishinev, Moldova)</p> <p><b>Decompensation of chronic heart failure (diagnostics and treatment)</b> D. Lysiy (Kishinev, Moldova)</p>
<p>20:30-20:40 <i>(Almaty)</i> 17:30-17:40 <i>(MSK)</i></p>	<p><b>Hall 1 (Almaty)</b> <b>Closing session</b></p>				